What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection.

Kathy Ingebrand of Mahtomedi is one of the first people in the country to receive the infusion meant to slow down Alzheimer's disease by up to 35%.

Recent health developments include Eli Lilly's Alzheimer's treatment approval in China, a DOJ lawsuit against CVS for opioid ...

It’s important to connect with loved ones this time of year but when Alzheimer’s is in the mix, it can be extra stressful.

AFP is a leading global news agency providing fast, comprehensive and verified coverage of the events shaping our world and of the issues affecting our daily lives. Drawing from an unparalleled ...